Startup Of The Week: IVFmicro
IVFmicro is a spinout from the University of Leeds, founded by Virginia Pensabene, Ph.D., and Helen Picton, B.Sc., Ph.D. The company has developed a patented microfluidic device designed to enhance IVF by improving embryo quality and quantity during a…
IVFmicro is a spinout from the University of Leeds, founded by Virginia Pensabene, Ph.D., and Helen Picton, B.Sc., Ph.D. The company has developed a patented microfluidic device designed to enhance IVF by improving embryo quality and quantity during a cycle. This technology addresses low IVF success rates by creating a safer, more stable environment for embryo development outside the womb.
IVFmicro, a University of Leeds spinout, is focused on improving IVF success rates through enhanced embryo culture processes. Traditional IVF involves fertilized eggs being carefully grown, transported, and monitored in a lab, which requires significant expertise. IVFmicro's microfluidic device aims to simplify this process by providing a safer environment for embryo handling.
The device uses microfluidics to mimic the natural conditions embryos experience in the body, enhancing both the quality and quantity of embryos. This technology is intended for use in any IVF cycle and aims to increase the number of viable embryos for transfer and freezing, thereby improving the chances of successful implantation and pregnancy.
Founded in 2024, IVFmicro recently secured £3.5 million in pre-seed funding to advance its technology in fertility clinics.
IVFmicro is a spinout from the University of Leeds, founded by Virginia Pensabene, Ph.D., and Helen Picton, B.Sc., Ph.D.
IVFmicro's patented device differs from conventional petri dish methods by using controlled fluid dynamics to simulate conditions in the fallopian tubes. This eliminates the need for mineral oil, which is traditionally used in IVF but can be toxic and costly. The device also includes a shockproof central culture chamber, enhancing embryo protection during lab procedures. This approach has demonstrated at least a 15% improvement in embryo production.
Market Potential in the Fertility Sector
The fertility treatment market is expanding, driven by a global infertility rate affecting 1 in 6 couples. Current IVF success rates are low, ranging from 20% to 40% for women under 40, decreasing significantly with age. A considerable percentage of embryos fail to develop, necessitating multiple costly treatment cycles. IVFmicro addresses these inefficiencies by improving embryo survival and development, thereby reducing the need for repeated treatments.
IVFmicro's main product is the Microfluidic Embryo Culture Device, a Class IIa medical device designed for fertility clinics. It features an entrance port, microfluidic channels, and a shockproof culture chamber, replicating in vivo conditions without using toxic oil. For more information, visit ivfmicro.com .
Based on reporting by techround.co.uk.
